source
- AstraZeneca’s experimental COPD drug tozorakimab cuts flare-ups by 30% in Phase 3 trialsIn two Phase 3 studies, AstraZeneca’s injectable COPD candidate tozorakimab reduced the rate of disease exacerbations by roughly 30%, according to data released on Tuesday. The trials measured flar…
- FDA approves AstraZeneca's new breast cancer therapyThe U.S. Food and Drug Administration has granted approval for AstraZeneca's latest breast cancer drug, expanding treatment options for patients with the disease. The approval follows a review of…